Metastatic Castration-resistant Prostate Cancer Clinical Trials in Atlanta, Georgia

4 studies are recruiting for metastatic castration-resistant prostate cancer in Atlanta, Georgia right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

    The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of DZR123 (Tulmimetostat, CPI-0209), both as monotherapy and in combination with enzalutamide, in patients with advanced solid t…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Winship Cancer Institute of Emory University, Atlanta, Georgia
    Locations
    80 in total
    Run by
    Novartis Pharmaceuticals

    See if you can join NCT04104776 on ClinicalTrials.gov

  2. A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

    The purpose of this study is to evaluate the safety, efficacy, tolerability, and pharmacokinetics (PK) of FG-3246, a cluster of differentiation 46 (CD46) targeting antibody-drug conjugate (ADC), in the treatment of participants with mCRPC who have progressed following treatment with one prior secon…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Winship Cancer Institute, Emory University, Atlanta, Georgia
    Locations
    23 in total
    Run by
    Kyntra Bio

    See if you can join NCT06842498 on ClinicalTrials.gov

  3. Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

    Phase I: Characterize safety and tolerability of GVV858 as a single agent and in combination with fulvestrant or letrozole. Identify dose range for optimization/recommended dose for further clinical evaluation. Phase II: Further characterize the safety and tolerability of GVV858 in combination with…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Emory University, Atlanta, Georgia
    Locations
    15 in total
    Run by
    Novartis Pharmaceuticals

    See if you can join NCT07288359 on ClinicalTrials.gov

  4. Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection

    To determine the dose, safety, radiation dosimetry and efficacy of 177Lu-rhPSMA-10.1 in participants with PSMA-expressing metastatic castrate resistant prostate cancer.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Emory University Hospital, Atlanta, Georgia
    Locations
    21 in total
    Run by
    Blue Earth Therapeutics Ltd

    See if you can join NCT05413850 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.